Tagged regenerative-biologic-products

Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy
Press Release

Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

 Extracellular vesicle product ExoFlo clinical trials to address early-stage COVID-19. Read More